The favorable impact of PIK3CA mutations on survival: An analysis of 2587 patients with breast cancer

Chinese Journal of Cancer

Volumn 31, Issue 7, 2012, Pages 327-334

  Dumont, Amaury G ^a,b   Dumont, Sarah N ^b   Trent, Jonathan C ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Breast cancer; Mutation; PI3K; PIK3CA gene

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; BUPARLISIB; PICTRELISIB; TAMOXIFEN; XL 147; XL 765;

ACTIN FILAMENT; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE MUTATION; HUMAN; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PIK3CA GENE; POSTMENOPAUSE; PREDICTION; REVIEW; SENESCENCE; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR DIAGNOSIS; TUMOR GENE;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CELL AGING; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MUTATION; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; SURVIVAL RATE;

EID: 84864395175     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10032     Document Type: Review

References (43)

1. Kang S, Bader AG, Zhao L, et al. Mutated PI 3-ki nases: cancer targets on a silver platter. Cell Cycle, 2005,4:578-581.
2. Amzel LM, Huang CH, Mandelker D, et al. Structural comparisons of class I phosphoinositide 3-ki nases. Nat Rev Cancer, 2008,8:665-669.
3. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-ki nases as regulators of growth and metabolism. Nat Rev Genet, 2006,7:606-619.
4. Cantley LC. The phosphoinositide 3-ki nase pathway. Science, 2002,296:1655-1657.
5. Katso R, Okkenhaug K, Ahmadi K, et al. Cellular function of phosphoinositide 3-ki nases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol, 2001,17: 615-675.
6. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol, 2006,18:77-82.
7. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther, 2004,3:772-775.
8. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res, 2004,64:7678-7681.
9. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer, 2006,94:455-459.
10. Ligresti G, Militello L, Steelman LS, et al. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle, 2009,8:1352-1358.
11. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science, 2004,304:554. http://www.sanger.ac.uk/genetics/CGP/cosmic/.
12. http://www.sanger.ac.uk/genetics/CGP/cosmic/.
13. Hollestelle A, Elstrodt F, Nagel JH, et al. Phosphatidylinositol-3-OH kinase or ras pathway mutations in human breast cancer cell lines. Mol Cancer Res, 2007,5:195-201.
14. Meyer DS, Brinkhaus H, Muller U, et al. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res, 2011,71:4344-4351.
15. Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res, 2005,65:10992-11000.
16. Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res, 2009,15:5049-5059.
17. Maruyama N, Miyoshi Y, Taguchi T, et al. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res, 2007,13:408-414.
18. Barbareschi M, Buttitta F, Felicioni L, et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res, 2007,13: 6064-6069.
19. Loi S, Haibe-Kains B, Majjaj S, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-po sitive breast cancer. Proc Natl Acad Sci U S A, 2010,107:10208-10213.
20. Michelucci A, Di Cristofano C, Lami A, et al. PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. Diagn Mol Pathol, 2009,18:200-205.
21. Boyault S, Drouet Y, Navarro C, et al. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat, 2011,132:29-39.
22. Perez-Tenorio G, Alkhori L, Olsson B, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res, 2007,13:3577-3584.
23. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res, 2005,65:2554-2559.
24. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res, 2008,68: 6084-6091.
25. Lai YL, Mau BL, Cheng WH, et al. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol, 2008,15:1064-1069.
26. Li SY, Rong M, Grieu F, et al. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat, 2006,96:91-95.
27. Lerma E, Catasus L, Gallardo A, et al. Exon 20 PIK3CA mutations decreases survival in aggressive (Her-2 positive) breast carcinomas. Virchows Arch, 2008,453:133-139.
28. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature, 2000,406:747-752.
29. Pang H, Flinn R, Patsialou A, et al. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class Ia phosphoinositide 3-ki nase. Cancer Res, 2009,69:8868-8876.
30. Yoeli-Lerner M, Yiu GK, Rabinovitz I, et al. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell, 2005,20:539-550.
31. Dupont Jensen J, Laenkholm AV, Knoop A, et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res, 2011,17:667-677.
32. Gorgoulis VG, Halazonetis TD. Oncogene-in duced senescence: the bright and dark side of the response. Curr Opin Cell Biol, 2010,22:816-827.
33. Campisi J, Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol, 2007,8:729-740.
34. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature, 2004,432:307-315.
35. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev, 2009:CD001877.
36. Pourreau-Schneider N, Berthois Y, Mittre H, et al. Estrogen response of MCF-7 cells grown on diverse substrates and in suspension culture: promotion of morphological heterogeneity, modulation of progestin receptor induction; cell-su bstrate interactions on collagen gels. J Steroid Biochem, 1984,21:763-771.
37. Stracke ML, Aznavoorian SA, Beckner ME, et al. Cell motility, a principal requirement for metastasis. EXS, 1991,59:147-162.
38. Hernandez-Aya LF, Gonzalez-Angulo AM. Targeting the phos-phatidylinositol 3-ki nase signaling pathway in breast cancer. Oncologist, 2011,16:404-414.
39. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-ki nase and antiestrogen resistance in breast cancer. J Clin Oncol, 2011,29:4452-4461.
40. Peyton JD, Rodon Ahnert J, Burris H, et al. A dose-es calation study with the novel formulation of the oral pan-cl ass I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. J Clin Oncol, 2011,29 (suppl):abstr 3066.
41. Janku F, Tsimberidou AM, Garrido-Laguna I, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/ AKT/mTOR axis inhibitors. Mol Cancer Ther, 2011,10:558-565.
42. Edelman G, BEDELL C, Shapiro G, et al. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol, 2010,28(suppl):abstr 3004.
43. Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-C lass I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol, 2011,30: 282-290.